|
iQur Board of Directors
Jack
B Boyer
William
Rosenberg
Bruce
Campbell
Brenda
Reynolds
Jack
B Boyer
Non-Executive Chairman
Mr Boyer joined iQur as Chairman in 2004. He previously founded and was
the CEO
of Trident Components Group, a €280 million revenue pan-European
engineering
group. Prior to that he was Chair and/or CEO of companies in the
manufacturing
sector and worked at Goldman Sachs and Bain & Co. He was educated
at Stanford
University
(B.A. Hons), the London
School of Economics (M.Sc.) and INSEAD (MBA). Mr Boyer leads the University of Southampton’s corporate
spin-out and
intellectual property exploitation activities as Chair of Southampton
Asset
Management and is a non-executive Chairman of early-stage companies in
emerging
technologies. He is also a Trustee of environmental and educational
non-profit
organizations.
Professor William Rosenberg
Founder, Chief
Scientific Officer and
Chief Executive Officer
William
Rosenberg was educated at the University
of Cambridge and Guy’s
Hospital, London,
qualifying in
medicine in 1983. His early medical training was at the MRC-CRC in Northwick Park,
London, before moving to Oxford as a
clinical registrar in 1987. In
1988 he entered John Bell’s laboratory in The Institute of
Molecular Medicine
as a Wellcome Trust Clinical Research Training Fellow.
After
completing his DPhil,
he returned to clinical work, as Clinical Tutor in Medicine in the University of Oxford, a post he held for five
years.
In this role William
completed his
clinical training in gastroenterology, hepatology and general medicine,
led an
MRC funded research group involved in molecular and immunological
science, and
gained extensive experience in clinical research and medical education.
In 1997, William moved to Southampton
with the remit of developing a service for hepatitis C. Over the last
seven
years, his group has grown to span epidemiology, clinical research, and
basic
science. Founded on IP emerging from this basic science research, he
began iQur
Ltd, the first spin-out company within the School
of Medicine at the University of Southampton.
He was
Professor of
Hepatology in the University
of Southampton, and chaired
the School
of Medicine Liver
Group. William became
Director of
the Wellcome Trust Clinical Research Facility in 2003, and took up
Directorship
of the Southampton University NHS Trust R&D office in 2005. In 2006
he
became Associate Director for Experimental Medicine in the UK
Clinical
Research Network (UKCRN).
William Rosenberg currently holds the
Richard Cristin
Chair of Hepatology University College London and Joint Head of Centre
for
Hepatology University College London.
He is
Director of the UCLH/UCL Clinical Research Facility incorporating the
Wellcome
Trust CRF and Cancer CRF. He is also Lead for Viral Hepatitis and
Consultant
Hepatologist, UCLH Foundation NHS Trust and Consultant Hepatologist,
Royal Free
Hampstead NHS Trust
His
national work with the NIHR involves co-ordination of translational
research
and the development of links between the NHS, Industry and Academia.
His main
research interests are in the immunology of viral hepatitis and
biomarkers of
chronic liver disease.
Professor
Rosenberg was
appointed CEO of iQur in February 2007.
Dr Bruce Campbell
Non-Executive Director
Bruce Campbell joined iQur Ltd in 2005. He is also the non-executive
Chairman
of Proximagen Neuroscience plc, Chief Scientific Officer and a director
of
IP2IPO Group plc, a director of Modern Biosciences plc and a
non-executive
director of Synairgen plc and Proximagen Ltd.
Formerly,
Dr Campbell was
Senior VP of International Development at Neurocrine Biosciences, Inc.
Prior to
joining this NASDAQ listed biotechnology company, Dr Campbell worked
for 27
years at Servier (United
Kingdom), latterly as Scientific
Director.
In addition, he has also been a director and European Chairman of the
Drug
Information Association and a member of the European ICH Safety Working
Party.
Dr Campbell
is a visiting
Professor in Pharmacology at King’s College, London. He has specific expertise on
the
practical and regulatory aspects of clinical pharmacology,
pharmacokinetics,
metabolism and toxicology in new drug development and has written
standard
texts on these subjects and published more than 100 scientific papers.
Brenda Reynolds
Non-Executive Director
In addition
to her
non-executive director role at iQur, Brenda Reynolds is currently
Managing
Director of PowderMed Ltd part-time, a director of PowderJect Research
Ltd and
an independent consultant to other Biotech companies. She was a founder
of
PowderMed Ltd in May 2004 and was Chief Operating Officer from its
inception
through to its sale to Pfizer in December 2006.
As Vice
President of
Portfolio and Programme Management at Powderject Holdings PLC she had
Global
responsibility for Portfolio Design and management, ensuring that all
projects
and their objectives were strategically aligned, subsequently
recommending and
implementing a business refocus on Vaccines. Previous to this, Brenda
held a
number of positions across the Healthcare sector. As Programme manager
for
Sexual Health at Pfizer she was responsible for the Viagra franchise.
Previous
to this she was a Director of Scotia Holdings PLC holding a number of
positions
there including Business Director for Oncology, developing a new
photodynamic
agent and laser system, Managing Director of an Animal Health business,
which
she subsequently divested, and Director of Preclinical
Development.
Other roles
included Head of European Project Management for G D Searle and Co. and
Regulatory Affairs manager at Beecham Research Labs. Brenda holds a
degree in
Toxicology, is a Chartered Director and a Fellow of the Royal Society
of
Medicine.
|
